QuidelOrtho Corporation (QDEL)
After hours:
| Previous Close | 39.68 |
| Open | 41.57 |
| Bid | 42.15 x 400 |
| Ask | 42.22 x 800 |
| Day's Range | 39.10 - 43.07 |
| 52 Week Range | 37.78 - 90.45 |
| Volume | |
| Avg. Volume | 1,201,513 |
| Market Cap | 2.824B |
| Beta (5Y Monthly) | 0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
SAN DIEGO, May 02, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and transfusion medicine, announced the Company’s Board of Directors (the "Board") has appointed Brian J. Blaser as President and Chief Executive Officer ("CEO") effective May 6. In addition to his appointment as President and CEO, Mr. Blaser will join the Board, effective May 15, 2024
- Business Wire
QuidelOrtho To Report First Quarter 2024 Financial Results
SAN DIEGO, April 17, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial results for its first quarter ended March 31, 2024, after the market close on Wednesday, May 8, 2024.
- Business Wire
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
SAN DIEGO, April 10, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay ("MPA"). This Fentanyl assay will help hospital and emergency room customers respond to the critical demand for enhanced opioid testing, allowing on-site fentanyl testing in less than 10 minutes to aid in immediate clinical decisions.
